Toxicity, Ethylene Glycol Workup

  • Author: Daniel C Keyes, MD, MPH; Chief Editor: Asim Tarabar, MD   more...
 
Updated: Jan 25, 2010
 

Laboratory Studies

Patients who ingest ethylene glycol may initially have few, if any, metabolic disturbances. Serum concentrations of ethylene glycol may be measured; however, at some health care facilities, these results are not available for 2 or more days. Thus, ethylene glycol levels are often not determined early enough to be useful in emergency treatment. For institutions that frequently treat ethylene glycol toxicity cases, in-hospital rapid laboratory confirmation may become cost-effective because of the institutional cost-benefit ratio evaluation that compares antidotal therapy, ethanol therapy, and hemodialysis therapy. Emergency departments located in larger metropolitan areas may negotiate availability of this test at regional clinical laboratories.

A study by Long et al suggests that a rapid qualitative colorimetric test (ethylene glycol test [EGT] kit), already in use by veterinarians, may be used by medical facilities as well. Using ethylene glycol added to human samples, the reported sensitivity was 100% (95% confidence interval [CI], 70-100%), and specificity was 88.8% (95% CI, 52-100%).[3] Although the use of such a test is promising, it has not been validated in human exposures and is thus not widely available to clinicians.

  • Serum osmolality: Because ethylene glycol levels are not reported in a clinically helpful fashion in most institutions, ethylene glycol exposure level is often estimated through measurement of the serum osmolality. This estimate is obtained by sampling a set of electrolyte levels (eg, BUN, creatinine, glucose) and calculating the expected osmolality in the patient's serum. A serum osmolality is then measured, and the difference between the measured and calculated osmolality (the osmolal gap) is determined. Several formulas are effective for calculating the osmolality from serum electrolytes and other solutes.
    • The most commonly used formula is 2(Na+ level) + BUN level/3 + glucose level/18 = calculated osmolality. The sodium level is measured in mEq, and the BUN and glucose levels are measured in mg/dL.
    • The osmolal gap is determined by subtracting the calculated osmolality from the measured osmolality (osmol [measured] - osmol [calculated] = osmolal gap). The serum osmolality must be determined by freezing-point depression rather than by boiling point elevation. This is because, with the boiling technique, the toxic alcohols are vaporized rapidly, and, thus, a falsely low or normal estimate of the osmolality is obtained. Once the osmolal gap is determined, estimating the serum levels of ethylene glycol or another alcohol is possible by applying the following conversion factors: ethylene glycol = 6.2, methanol = 3.2, and ethanol = 4.6.
    • If the ethanol level is measured simultaneously with the electrolyte levels, its contribution can be subtracted to determine an approximate contribution of the toxic alcohol. If the clinician does not wish to memorize the conversion factors, they can be calculated by dividing the molecular weight by 10. For example, the conversion factor for ethanol would be calculated by adding the molecular weight of 2 carbons = 2 X 12, 1 oxygen = 16, and 6 hydrogens = 6. Thus, 24 + 16 + 6 = 46. This divided by 10 reveals the conversion factor for ethanol, which is 4.6. Most clinicians prefer to look these values up in a table.
    • Serum electrolyte levels are also useful later in the course of intoxication because they can reveal the presence of anion gap acidosis. This information may be important when determining the need for dialysis and other interventions. The goal of therapy, however, is to treat the patient before acidosis develops.
  • Additional laboratory tests that should be obtained in symptomatic patients include the following:
    • Serum calcium level determination is recommended.
    • Arterial blood gas determination is recommended.
    • Urinalysis: Urine may reveal the presence of calcium oxalate crystals, a sign usually observed late in the process of intoxication. Oxalate crystals typically have the shape of a folded envelope.
    • Another technique, popularized by the television series "ER," is to shine a Wood lamp (UV light) on an early sample of urine. If a sufficient fluorescein level is present in the radiator fluid, the urine fluoresces.[4] The urine should be compared to a control sample. If the radiator fluid contains fluorescein, a green-colored glow may be observed in a dark room. This light also may be used to detect possible ethylene glycol on clothing or the patient.
Next

Imaging Studies

Imaging rarely contributes to the specific diagnosis of ethylene glycol intoxication, but it may be useful as needed for routine care of these patients.

Previous
Next

Other Tests

Other tests that may be useful depending on the clinical status of the patient include electrocardiography (ECG) and CT scan of the brain. Use of a Wood's (ultraviolet) lamp has been discussed above. A microscope may be useful for identifying calcium oxalate crystals, as noted above.

Previous
 
 
Contributor Information and Disclosures
Author

Daniel C Keyes, MD, MPH  Vice Chair, Academic Affairs, Department of Emergency Medicine, John Peter Smith Health Network; Clinical Associate Professor, Department of Surgery, Division of Emergency Medicine and Toxicology, University of Texas Southwestern School of Medicine

Daniel C Keyes, MD, MPH is a member of the following medical societies: American College of Emergency Physicians, American College of Medical Toxicology, American College of Occupational and Environmental Medicine, and American College of Physicians-American Society of Internal Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Miguel C Fernandez, MD, FAAEM, FACEP, FACMT, FACCT  Associate Clinical Professor; Medical and Managing Director, South Texas Poison Center, Department of Surgery/Emergency Medicine and Toxicology, University of Texas Health Science Center at San Antonio

Miguel C Fernandez, MD, FAAEM, FACEP, FACMT, FACCT is a member of the following medical societies: American Academy of Emergency Medicine, American College of Clinical Toxicologists, American College of Emergency Physicians, American College of Medical Toxicology, American College of Occupational and Environmental Medicine, Society for Academic Emergency Medicine, and Texas Medical Association

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD  Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM,  Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD  Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

References
  1. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila). Dec 2008;46(10):927-1057. [Medline]. [Full Text].

  2. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila). Dec 2009;47(10):911-1084. [Medline]. [Full Text].

  3. Long H, Nelson LS, Hoffman RS. A rapid qualitative test for suspected ethylene glycol poisoning. Acad Emerg Med. Jul 2008;15(7):688-90. [Medline].

  4. LeBlanc C, Murphy N. Should I stay or should I go?: toxic alcohol case in the emergency department. Can Fam Physician. Jan 2009;55(1):46-9. [Medline].

  5. [Guideline] Caravati EM, Erdman AR, Christianson G, Manoguerra AS, Booze LL, Woolf AD, et al. Ethylene glycol exposure: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(5):327-45. [Medline]. [Full Text].

  6. [Guideline] Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol. 1999;37(5):537-60. [Medline].

  7. Druteika DP, Zed PJ, Ensom MH. Role of fomepizole in the management of ethylene glycol toxicity. Pharmacotherapy. Mar 2002;22(3):365-72. [Medline].

  8. Corley RA, McMartin KE. Incorporation of therapeutic interventions in physiologically based pharmacokinetic modeling of human clinical case reports of accidental or intentional overdosing with ethylene glycol. Toxicol Sci. May 2005;85(1):491-501. [Medline]. [Full Text].

  9. Green R. The management of severe toxic alcohol ingestions at a tertiary care center after the introduction of fomepizole. Am J Emerg Med. Sep 2007;25(7):799-803. [Medline].

  10. Megarbane B, Borron SW, Baud FJ. Current recommendations for treatment of severe toxic alcohol poisonings. Intensive Care Med. Feb 2005;31(2):189-95. [Medline].

  11. Velez LI, Shepherd G, Lee YC, Keyes DC. Ethylene glycol ingestion treated only with fomepizole. J Med Toxicol. Sep 2007;3(3):125-8. [Medline].

  12. Baud FJ, Galliot M, Astier A, Bien DV, Garnier R, Likforman J. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med. Jul 14 1988;319(2):97-100. [Medline].

  13. Brent J. Current management of ethylene glycol poisoning. Drugs. 2001;61(7):979-88. [Medline].

  14. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med. Mar 18 1999;340(11):832-8. [Medline].

  15. Browning RG, Curry SC. Clinical toxicology of ethylene glycol monoalkyl ethers. Hum Exp Toxicol. May 1994;13(5):325-35. [Medline].

  16. Burkhart K. Methanol and ethylene glycol toxicity. J Toxicol Clin Toxicol. 1997;35(2):149-50. [Medline].

  17. Carney EW. An integrated perspective on the developmental toxicity of ethylene glycol. Reprod Toxicol. Mar-Apr 1994;8(2):99-113. [Medline].

  18. Church AS, Witting MD. Laboratory testing in ethanol, methanol, ethylene glycol, and isopropanol toxicities. J Emerg Med. Sep-Oct 1997;15(5):687-92. [Medline].

  19. Darchy B, Abruzzese L, Pitiot O, et al. Delayed admission for ethylene glycol poisoning: lack of elevated serum osmol gap. Intensive Care Med. Aug 1999;25(8):859-61. [Medline].

  20. Davis DP, Bramwell KJ, Hamilton RS, Williams SR. Ethylene glycol poisoning: case report of a record-high level and a review. J Emerg Med. Sep-Oct 1997;15(5):653-67. [Medline].

  21. Glaser DS. Utility of the serum osmol gap in the diagnosis of methanol or ethylene glycol ingestion. Ann Emerg Med. Mar 1996;27(3):343-6. [Medline].

  22. Sabeel AI, Kurkus J, Lindholm T. Intensified dialysis treatment of ethylene glycol intoxication. Scand J Urol Nephrol. Jun 1995;29(2):125-9. [Medline].

  23. Wallace KL, Suchard JR, Curry SC, Reagan C. Diagnostic use of physicians' detection of urine fluorescence in a simulated ingestion of sodium fluorescein-containing antifreeze. Ann Emerg Med. Jul 2001;38(1):49-54. [Medline].

  24. Winter ML, Ellis MD, Snodgrass WR. Urine fluorescence using a Wood's lamp to detect the antifreeze additive sodium fluorescein: a qualitative adjunctive test in suspected ethylene glycol ingestions. Ann Emerg Med. Jun 1990;19(6):663-7. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.